Sugi Predict

Sugi Predict / Compounds / SCHEMBL23358166

SCHEMBL23358166

SCHEMBL23358166

CC1(O)C[C@H]2CC[C@@H](C1)N2C(=O)OC(C)(C)C

nearest known ligand 0.60

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ CHRM2 P08172 1/20 0.60
▸ CHRM1 P11229 1/20 0.60
▸ CHRM3 P20309 1/20 0.60
▸ PREP P48147 4/20 0.46
▸ HSD11B1 P28845 2/20 0.43
▸ HPGD P15428 1/20 0.36
▸ EPHX2 P34913 1/20 0.36
▸ GRM5 P41594 2/20 0.36
▸ USP2 O75604 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ RECQL P46063 1/20 0.35
▸ EPHX1 P07099 1/20 0.35
▸ GPR119 Q8TDV5 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20224852 1.00 CHRM2 (0.60) CHRM2CHRM1CHRM3PREPHSD11B1
SCHEMBL4467476 1.00 CHRM2 (0.60) CHRM2CHRM1CHRM3PREPHSD11B1
SCHEMBL13132892 1.00 CHRM2 (0.60) CHRM2CHRM1CHRM3PREPHSD11B1
SCHEMBL2708315 1.00 CHRM2 (0.60) CHRM2CHRM1CHRM3PREPHSD11B1
SCHEMBL26923463 0.90 CHRM2 (0.56) CHRM2CHRM1CHRM3PREPHSD11B1
SCHEMBL29367803 0.87 CHRM2 (0.57) CHRM2CHRM1CHRM3PREPHSD11B1
SCHEMBL12979471 0.85 CHRM2 (0.58) CHRM2CHRM1CHRM3PREPHSD11B1
SCHEMBL25188952 0.85 CHRM2 (0.58) CHRM2CHRM1CHRM3PREPHSD11B1
SCHEMBL23264900 0.83 CHRM2 (0.53) CHRM2CHRM1CHRM3PREPHSD11B1
SCHEMBL2708301 0.83 CHRM2 (0.61) CHRM2CHRM1CHRM3PREPHSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3233077-B1 DOPAMINE D2 RECEPTOR LIGANDS BROAD INST INC (US) 2026-05-06 — — EP disclosed
US-12428373-B2 Dopamine D2 receptor ligands THE BROAD INSTITUTE, INC. (US) 2025-09-30 — — US disclosed
US-20230143552-A1 DOPAMINE D2 RECEPTOR LIGANDS THE BROAD INSTITUTE, INC. (US) 2023-05-11 — — US disclosed
US-11498896-B2 Dopamine D2 receptor ligands THE BROAD INSTITUTE, INC. (US) 2022-11-15 — — US disclosed
CN-110357875-B Azabicyclooctane derivative, preparation method and medical application thereof 浙江海正药业股份有限公司 2022-06-21 — — CN disclosed
US-20210147355-A1 DOPAMINE D2 RECEPTOR LIGANDS THE BROAD INSTITUTE, INC. (US) 2021-05-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11498896-B2 Dopamine D2 receptor ligands DRD2, SLC6A3, NTSR2 CHRM2 166/4885CHRM1 253/4885CHRM3 159/4885
US-20230143552-A1 DOPAMINE D2 RECEPTOR LIGANDS DRD2, SLC6A3, NTSR2 CHRM2 166/4885CHRM1 253/4885CHRM3 159/4885
US-20210147355-A1 DOPAMINE D2 RECEPTOR LIGANDS DRD2, SLC6A3, NTSR2 CHRM2 166/4885CHRM1 253/4885CHRM3 159/4885
US-12428373-B2 Dopamine D2 receptor ligands DRD2, SLC6A3, NTSR2 CHRM2 166/4885CHRM1 253/4885CHRM3 159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.